Larchmont, NY, United States of America

Sumanta Goswami

USPTO Granted Patents = 2 



Average Co-Inventor Count = 4.0

ph-index = 2

Forward Citations = 25(Granted Patents)


Company Filing History:


Years Active: 2013-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Sumanta Goswami

Introduction

Sumanta Goswami is a notable inventor based in Larchmont, NY (US). He has made significant contributions to the field of cancer research, particularly in the diagnosis and treatment of metastatic tumors. With a total of 2 patents, his work has the potential to impact the medical community profoundly.

Latest Patents

Goswami's latest patents include groundbreaking methods and kits for the diagnosis, prognosis, and treatment of metastatic tumors. One of his patents focuses on metastasis-specific splice variants of Mena, which are characterized by changes in the expression of +++, ++, and/or 11a variants of Mena. This innovative approach aims to enhance the accuracy of tumor characterization and improve treatment outcomes.

Career Highlights

Throughout his career, Sumanta Goswami has worked with prestigious institutions such as Albert Einstein College of Medicine and the Massachusetts Institute of Technology. His experience in these renowned organizations has allowed him to collaborate with leading experts in the field and contribute to cutting-edge research.

Collaborations

Some of his notable coworkers include John S. Condeelis and Frank B. Gertler. Their collaborative efforts have further advanced the understanding of metastatic tumors and the development of effective diagnostic tools.

Conclusion

Sumanta Goswami's innovative work in cancer research and his contributions to the field through his patents highlight the importance of ongoing research in improving cancer diagnosis and treatment. His dedication to advancing medical science is commendable and serves as an inspiration for future inventors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…